We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Target prices reflect the market consensus (mean/high/low), not individual research firms. 11 actions collected · 11 in the last 12 months.
Auto-generated summary combining US and Korean research and earnings · not investment advice
Samsung Biologics has shown volatility in its recent quarterly revenue, ranging from 1.2 trillion won to 1.6 trillion won. Revenue for Q1 2026 was approximately 1.25 trillion won, and EPS for that quarter was not provided. IBK Investment & Securities and Daishin Securities recently maintained their ratings. Currently, consensus target price information is not available.
Divergence: Both IBK Investment & Securities and Daishin Securities maintained their investment opinions, showing a consistent view.
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 07. 24. | IBK투자증권 | — | Maintain | — → — | — | 미국 생산거점과 5공장, 그리고 펩타이드 |
| 2026. 07. 24. | iM증권 | — | Maintain | — → — | — | 성장을 이끄는 새로운 스토리가 생겼다 |
| 2026. 07. 24. | 키움증권 | — | Maintain | — → — | — | 록빌과 5공장으로 이어질 성장. 기대되는 4분.. |
| 2026. 07. 24. | 대신증권 | — | Maintain | — → — | — | 분기 최대 실적 달성, 3Q 쉬어가도 성장은 지.. |
| 2026. 07. 24. | DS투자증권 | — | Maintain | — → — | — | 2Q26 Re: 3분기부터 시작될 성장 랠리 |
| 2026. 07. 24. | 교보증권 | — | Maintain | — → — | — | 2Q26 Review; 방향성을 믿고 갈 때 |
| 2026. 07. 24. | 하나증권 | — | Maintain | — → — | — | 체급을 키우기 위한 약간의 성장통 (2Q26 Rev.. |
| 2026. 07. 21. | 키움증권 | — | Maintain | — → — | — | 글로벌 펩타이드 CDMO 인수로 사업 영역 확장 |
| 2026. 07. 21. | 대신증권 | — | Maintain | — → — | — | 항체를 넘어 펩타이드로 |
| 2026. 06. 29. | IBK투자증권 | — | Maintain | — → — | — | 하반기 불확실성 해소 기대 |
| 2026. 05. 20. | 대신증권 | — | Maintain | — → — | — | 규모의 경제가 만드는 복리 성장 |